Cellular models for human cardiomyopathy: What is the best option?

doi:10.4330/wjc.v11.i10.221

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8264)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

485

WORD

175

HTML

4735

Figures (1-3)

361

Tables (1-3)

257

Sum=6013

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

761

Download

1490

Sum=2251

Oct 26, 2019 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Cardiol. Oct 26, 2019; 11(10): 221-235
Published online Oct 26, 2019. doi: 10.4330/wjc.v11.i10.221

Full Size Figure Download Figure

Figure 3 Cardiomyocyte differentiation protocol. Modified from Lian et al[135], 2012. hiPSCs: Human induced pluripotent stem cells.

Citation: Jimenez-Tellez N, Greenway SC. Cellular models for human cardiomyopathy: What is the best option? World J Cardiol 2019; 11(10): 221-235
URL: https://www.wjgnet.com/1949-8462/full/v11/i10/221.htm
DOI: https://dx.doi.org/10.4330/wjc.v11.i10.221